Evidence map›Paper›PMID 27460074›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells.

Christos Vaklavas, William E Grizzle, Hyoungsoo Choi, Zheng Meng, Kurt R Zinn, Kedar Shrestha, Scott W Blume

Open access · hybridAbstract read
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. The Internal Ribosome Entry Site in Circular RNAs.Advances in experimental medicine and biology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Noncanonical Translation Initiation in Eukaryotes.Cold Spring Harbor perspectives in biology · 2019
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Christos VaklavasComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
William E GrizzleComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Hyoungsoo ChoiComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Zheng MengDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Bevill Biomedical Research Bldg Room 765, 845 19th Street S, Birmingham, AL, 35294, USA.
Kurt R ZinnComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Kedar ShresthaComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35294, USA.
Scott W BlumeComprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, 35294, USA. scblume704@gmail.com.
University of Alabama at Birmingham · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
Dysregulation of IGF-1R Translational ControlR01CA108886 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI BLUME, SCOTT W · 2004 to 2015
$2.3M
NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA108886
6 · The paper itself

Abstract

Internal ribosome entry site (IRES)-mediated translation is a specialized mode of protein synthesis which malignant cells depend on to survive adverse microenvironmental conditions. Our lab recently reported the identification of a group of compounds which selectively interfere with IRES-mediated translation, completely blocking de novo IGF1R synthesis, and differentially modulating synthesis of the two c-Myc isoforms. Here, we examine the phenotypic consequences of sustained IRES inhibition in human triple-negative breast carcinoma and glioblastoma cells. A sudden loss of viability affects the entire tumor cell population after ∼72-h continuous exposure to the lead compound. The extraordinarily steep dose-response relationship (Hill-Slope coefficients -15 to -35) and extensive physical connections established between the cells indicate that the cells respond to IRES inhibition collectively as a population rather than as individual cells. Prior to death, the treated cells exhibit prominent features of terminal differentiation, with marked gains in cytoskeletal organization, planar polarity, and formation of tight junctions or neuronal processes. In addition to IGF1R and Myc, specific changes in connexin 43, BiP, CHOP, p21, and p27 also correlate with phenotypic outcome. This unusual mode of tumor cell death is absolutely dependent on exceeding a critical threshold in cell density, suggesting that a quorum-sensing mechanism may be operative. Death of putative tumor stem cells visualized in situ helps to explain the inability of tumor cells to recover and repopulate once the compound is removed. Together, these findings support the concept that IRES-mediated translation is of fundamental importance to maintenance of the undifferentiated phenotype and survival of undifferentiated malignant cells.

Indexed as

Protein BiosynthesisAntineoplastic AgentsApoptosisBiomarkersCell DifferentiationCell Line, TumorCell SurvivalDose-Response Relationship, DrugFemaleGlioblastomaHumansInternal Ribosome Entry SitesNeoplastic Stem CellsNeuronsProtein BindingTight JunctionsAntineoplastic AgentsBiomarkersInternal Ribosome Entry SitesTubulinGlioblastomaHill slope coefficientQuorum-sensingTerminal differentiationTriple-negative breast cancer

Identifiers

PMID27460074
PMCPMC5097113
OpenAlexW2478485623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.